Checkout our iOS App for a better way to browser and research.
(1) Beginning January 1, 2022, a pharmacist may prescribe a prescription drug or device if:
(a) prescribing the prescription drug or device is within the scope of the pharmacist's training and experience;
(b) the prescription drug or device is designated by the division by rule under Subsection (3)(a); and
(c) the prescription drug or device is not a controlled substance that is included in Schedules I, II, III, or IV of:
(i) Section 58-37-4; or
(ii) the federal Controlled Substances Act, Title II, P.L. 91-513.
(2) Nothing in this section requires a pharmacist to issue a prescription for a prescription drug or device.
(3) The division shall make rules in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, to:
(a) designate the prescription drugs or devices that may be prescribed by a pharmacist under this section, beginning with prescription drugs or devices that address a public health concern that is designated by the Department of Health, including:
(i) post-exposure HIV prophylaxis;
(ii) pre-exposure HIV prophylaxis;
(iii) self-administered hormonal contraceptives;
(iv) smoking cessation; and
(v) naloxone;
(b) create guidelines that a pharmacist must follow when prescribing a prescription drug or device, including guidelines:
(i) for notifying the patient's primary care or other health care provider about the prescription; and
(ii) to prevent the over-prescription of drugs or devices including but not limited to antibiotics;
(c) address when a pharmacist should refer the patient to an appropriate health care provider or otherwise encourage the patient to seek further medical care; and
(d) implement the provisions of this section.
(4) The division shall make rules under Subsection (3) in collaboration with:
(a) individuals representing pharmacies and pharmacists;
(b) individuals representing physicians and advanced practice clinicians; and
(c)
(i) if the executive director of the Department of Health is a physician, the executive director of the Department of Health;
(ii) if the executive director of the Department of Health is not a physician, a deputy director who is a physician in accordance with Subsection 26-1-9(4); or
(iii) a designee of the individual described in Subsection (4)(c)(i) or (ii).
(5) Before November 1 of each year, the division, in consultation with the individuals described in Subsection (4), shall:
(a) develop recommendations for statutory changes to improve patient access to prescribed drugs in the state; and
(b) report the recommendations developed under Subsection (5)(a) to the Health and Human Services Interim Committee.